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Background: Human marrow stromal cells (hMSCs) injected intrathecally can effectively increase the lifespan and
protect motor neurons in a transgenic mouse model of amyotrophic lateral sclerosis. However, how the
transplanted cells exert a neuroprotective effect is still unclear. More recently, the anti-inflammation effect of
marrow stromal cells has generated a great deal of interest. In the present study, we sought to investigate whether
intrathecally injected hMSCs protect motor neurons through attenuating microglial activation and the secretion of
inflammatory factors in Cu/Zn superoxide dismutase 1 (SOD1) transgenic mice. In addition, we also focused on the
mode of hMSCs inhibiting microglial activation.
Methods: We transplanted hMSCs into the cisterna magna of SOD1 mice at the age of 8, 10 and 12 weeks. At sacrifice,
tissues were harvested for analysis of neuron counts, microglial activation, TNFα secretion and inducible nitric oxide
synthase (iNOS) protein expression. In vitro, microglial cells were treated with hMSC co-culture, hMSC transwell culture
or hMSC conditioned medium to investigate the mode of hMSCs exerting an anti-inflammation effect.
Results: Intrathecally transplanted hMSCs inhibited inflammatory response in SOD1 transgenic mice, which was
evidenced by the decreases in microglial activation, TNFα secretion and iNOS protein expression. In addition, the
inhibitory effect on microglial activation of hMSCs was through secretion of diffusible molecules adjusted to
environmental cues.
Conclusion: Intrathecally injected hMSCs can attenuate microglial activation through secretion of diffusible molecules
to exert a therapeutic effect in SOD1 transgenic mice. Further studies are needed to explore the exact mechanisms by
which hMSCs inhibit inflammation for facilitating the therapeutic effect.
Keywords: Amyotrophic lateral sclerosis, Bone marrow stromal cells, Cu/Zn superoxide dismutase 1, Intrathecal
transplantation, MicrogliaBackground
Amyotrophic lateral sclerosis (ALS) is a fatal neurode-
generative disorder characterized by progressive loss of
spinal cord and cortical motoneurons. A transgenic
mouse model expressing the human G93A mutant vari-
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reproduction in any medium, provided the oraccepted model of the disease [1]. Stem cell transplant-
ation is a promising therapeutic strategy for ALS. The
functional replacement of lost motoneurons is proved
to be very difficult, and more likely transplanted cells
exert their neuroprotective effect.
Human marrow stromal cells (hMSCs) are isolated
from adult bone marrow, and easy access suggests their
feasibility in clinical therapies. Marrow stromal cells
(MSCs) have the potential to differentiate to lineages of
mesenchymal tissues such as bone, cartilage, fat, tendon
and muscle [2]. A rare cell type within MSCs calledtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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stem cells, have been identified [3]. MSCs express a var-
iety of cytokines and trophic factors [4]. The role of
MSCs as nurse cells supporting the function of other cell
types in bone marrow suggests their potential use as
neuroprotective cells. Moreover, autologous transplant-
ation of these cells would circumvent potential ethical and
immunological concerns. The advantages suggest that
hMSCs may be suitable candidates for human therapies.
Our previous studies showed that multiple intrathecal ad-
ministration of hMSCs effectively increased the lifespan
and protected motorneurons in SOD1 mice, although very
few injected hMSCs were detected in the parenchyma of
spinal cord [5]. However, it is still unclear how the cells
injected intrathecally exert a neuroprotective effect.
Activated microglia and proinflammatory cytokines in-
cluding TNFα secreted by these cells appeared to play
an important role in disease progression of SOD1 trans-
genic mice [6]. Moreover, encouraging preliminary re-
sults have been obtained in SOD1 transgenic mice with
the cyclooxygenase-2 inhibitor, with which a 20% pro-
longation of survival was reported [7]. Targeting therapy
to microglia may therefore be an effective strategy for
ALS. More recently, the anti-inflammation effect of
MSCs as a protective mechanism has been demonstrated
in vitro [8-10] and in animal models of Parkinson dis-
ease [11], cerebral ischemia [12,13], Krabbe’s disease [14]
and ALS [15], which has generated a great deal of inter-
est. Locally injected hMSCs in the lumbar spinal of
SOD1 mice reduced microglial activation and reactive
astrocytosis [15], but whether the intrathecally injected
hMSCs inhibit microglial activation and attendant secre-
tion of inflammatory factors remains unclear.
In the present study, we sought to investigate whether
intrathecally injected hMSCs protect motor neurons by
attenuating microglial activation and inflammatory fac-
tor secretion in SOD1 transgenic mice. In addition, we




Transgenic mice of the strain B6SJL-TgN (SOD1-G93A)
1Gur, which harbor human SOD1 with the G93A muta-
tion in high copy number, were obtained from Jackson
Laboratory (Bar Harbor, Maine, USA). We maintained
the transgenic G93A hemizygotes by mating transgenic
males with B6SJLF1/J hybrid females. Transgenic mice
were identified by PCR using primers and a protocol
suggested by the vendor. All mice were housed in the
specific pathogen-free animal facility of Sun Yat-Sen
University, Guangdong, PR China. From the time when
transgenic mice showed motor deficits, nutritional gel was
routinely placed in the cages of all transgenic animals foreasy access to food and hydration. Transgenic mice were
randomly divided into two groups: Group 1, hMSC-
treated group – mice (n = 27) were intrathecally injected
with hMSCs at the age of 8, 10 and 12 weeks; Group 2,
vehicle-treated group – mice (n = 29) were administered
PBS at the age of 8, 10 and 12 weeks. Age-matched wild-
type littermate mice (n = 25) were used as the normal
control group. Experiments were conducted in accordance
with protocols approved by the Animal Care and Use
Committee of Sun Yat-Sen University. Ethical Approval
was given by Sun Yat-Sen University Research Ethics
Committee (reference number: ZS09072).
Preparation of human marrow stromal cells
After obtained informed consent, 2 ml bone marrow
was aspirated from the iliac crest of healthy normal vol-
unteers. This protocol was approved by the Institutional
Review Board of Sun Yat-Sen University. Mononuclear
cells were isolated by Ficoll density gradient centrifuga-
tion (1.077 g/ml; Sigma, Munich, Germany) at 400× g for
35 minutes. The mononuclear cells were resuspended in
the culture medium composed of DMEM (GIBCO,
Rockville, MD, USA) with low glucose and 10% fetal bo-
vine serum (FBS; Hyclone, Logan, UT, USA). The mono-
nuclear cells were plated at 1×106 cells/25 cm2 in
culture flasks and the cultures were incubated at 37°C
in 5% CO2 in air and 95% humidity. The medium was
exchanged after 48 hours and every 3 to 4 days thereafter.
When the cultures reached approximately 90% of conflu-
ence, hMSCs were passaged with 0.25% trypsin (GIBCO)
and replated into passage culture at a density of 5,000 to
10,000 cells/cm2. Cells at passages 3 and 4 were used for
transplantation. Upon harvest, cells were isolated by treat-
ment with 0.25% trypsin. The cells were then washed four
times and resuspended in PBS at a cellular density of
100,000 cells/μl. Viability of cells was assessed using a 0.4%
Trypan Blue dye (Sigma) exclusion method prior to and
following transplantation. The cells were analyzed for their
immunophenotype by flow cytometry (Beckman Coulter,
Fullerton, CA, USA). Fluorescein isothiocyanate (FITC)-
conjugated or phycoerythrin-conjugated antibodies specific
for human CD14, CD19, CD45, CD34, CD73, CD90,
CD105 and HLA-DR tested for flow cytometry applica-
tion. The percentage of positive cells was determined
based on the fluorescent emission of the nonspecific
FITC/phycoerythrin isotypic antibody controls.
Transplantation
Transgenic mice were anesthetized with pentobarbital
(60 mg/kg, intraperitoneally), and were placed in a prone
position with the head flexed below horizontal by ap-
proximately 30°. The posterior scalp was incised in the
midline and the muscles were separated by blunt dissec-
tion with forceps. At the junction of the occipital bone
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blood vessel can be seen (arteria dorsalis spinals). The
atlanto-occipital membrane was blotted dry and pierced
with a Hamilton syringe and 30-gauge needle 45° caud-
ally from the middle toward the left side. Cerebrospinal
fluid was aspirated to make sure that the tip of the nee-
dle was in the cisterna magna. Then 5 μl cell suspension
(approximately 5×105 hMSCs) or 5 μl vehicle (PBS) was
injected into the cisterna magna slowly over 5 minutes.
All animals were immunosuppressed with cyclosporine
(10 mg/kg, intraperitoneally, per day) 3 days before sur-
gery and thereafter.Assessment of disease progression
Beginning at 8 weeks of age, the mice were monitored
for disease onset and progression weekly by a well-
trained experienced observer blinded to the genotype.
We used testing methods including simple clinical ob-
servation and the hanging wire test. Onset was defined
retrospectively as the earliest time when the mice
showed symptoms (tremulousness and/or gait abnormal-
ities) for ≥2 consecutive weeks. Because of ethical con-
siderations, transgenic animals were euthanized when
they were unable to right themselves within 30 seconds,
and this time point was recorded as the time of death.
The hanging wire test evaluates paw grip endurance.
The mouse was placed on a wire cage lid and the lid was
gently waved in the air so that the mouse griped the
wire. The lid was then turned upside down approxi-
mately 50 cm above the surface of soft bedding material.
The latency until a mouse let loose with both hind limbs
was recorded, with a cutoff time of 90 seconds. Each
mouse was given three consecutive trials, and the lon-
gest latency was recorded.Spinal cord history and neuron counts
The mice (n = 4 each) at the ages of 11 weeks (a time
point of presymptom) and 15 weeks (a time point of full
symptoms) were killed under deep chloral hydrate (10%)
anesthesia. Mice were intracardially perfused with 0.1 M
PBS (pH 7.4) for 1 minute, followed by cold 4% parafor-
maldehyde in PBS (pH 7.4) for 10 minutes. The spinal
cords were dissected carefully, and the lumbar segment
was identified using the ribs and the vertebrate as a
guide. Tissues were postfixed in 4% paraformaldehyde
for 6 hours. Blocks were cryoprotected in 30% sucrose
for 24 hours, and then were embedded transversely in
OCT compound (Tissue TekW, Elkhart, IN, USA). They
were then serially sectioned for 2 mm of the lumbar en-
largement at 10 μm on a cryostat. Sections were
mounted on gelatinized glass slides and stored at −20°C.
A set of sections included 15 sections in total (every fifth
section to avoid false double-counting) from eachanimal. Both right and left hind limbs were studied and
the results were averaged.
For neuron counts, a section was stained with 1% cre-
syl violet. Cell counts were made within an area demar-
cated by a horizontal line drawn through the central
canal and encompassing the ventral horn of grey matter
to include layers 7 to 9. Each section was visualized with
an light microscope (Olympus B×51, Tokyo, Japan) at
200× magnifications, captured onto a computer using
Image-pro-plus 5.1(Media Cybernetics Inc, Silver Spring,
MD, USA) and counted manually by tracing the perim-
eter of each motor neuron. We identified motoneurons
and analyzed them for cell area using the following cri-
teria [7]: the presence of a large single nucleolus located
within the nucleus, surrounded by light blue staining
cytoplasm; and a cell somal area over 100 μm2. Gamma
motor neurons range from 100 to 250 μm2, whereas the
larger α motor neurons range from 250 to 1,100 μm2.
For immunohistochemistry, sections were permeabilized
in 0.3% Triton X-100, blocked with normal serum, and
then incubated with primary antibody at 4°C overnight.
Primary antibodies included: rat anti-mouse CD11b (1:50
dilution; Chemicon, Temecula, CA, USA). Sections were
washed and incubated at room temperature for 1 hour
with goat anti-rat FITC-conjugated IgG (1:50 dilution;
Serotec, Raleigh, NC, USA). All staining involved the use
of a negative control (secondary antibody alone) in order
to evaluate the specificity of the antibodies. Three different
states of microglia activation, ranging from resting to
intermediate and fully activated according to their mor-
phological appearance, were determined and then quanti-
fied by a rater blinded to the treatment group. Resting
microglial cells have a ramified morphology with a rela-
tively small body. Intermediate activated microglial cells
display a strong expression of CD11b, shortening pro-
cesses. Fully activated microglial cells adopt a round,
macrophage-like morphology. Quantification of microglia
was made by manually counting CD11b+ cells in the ven-
tral horn of gray matter to include layers 7 to 9 of the
spinal cord at 400× magnifications.
Spinal cord TNFα ELISA
Wild-type control mice, hMSC-treated and vehicle-treated
transgenic mice at 11 weeks of age (four mice each group)
were killed by decapitation, and the lumbar spinal cord
was rapidly removed and frozen in isopentane at −35°C on
dry ice. Spinal cord samples were placed in ice-cold lysis
buffer containing protease inhibitor, homogenized using a
homogenizer, and centrifuged at 13,000× g for 30 minutes
at 4°C. Protein concentrations from supernatant were
determined using a Bio-Rad protein assay (Bio-Rad,
Hercules, CA, USA ). The supernatant was removed and
stored in −80°C in aliquots for ELISA and western blotting
studies. TNFα concentrations were determined by a mice-
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CA, UAS) according to the manufacturer’s instructions.
Western blotting
Briefly, protein extracts (20 μg) of the lumbar enlarge-
ment were boiled in loading buffer for 3 minutes and
were subsequently loaded into wells of 12% SDS-
polyacrylamide gels at 80 V for 30 minutes and at 150 V
for 90 minutes. Proteins were then transferred onto
polyvinylidene difluoride membranes (Minipore, Bedford,
MA, USA). The blots were blocked with 5% (w/v) defat-
ted milk in TBS-Tween20 (pH 8.0) for 1 hour at room
temperature and then incubated overnight at 4°C with
primary antibodies: polyclonal rabbit anti-mouse indu-
cible nitric oxide synthase (iNOS) (1:1,000; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and mouse anti-
actin (1:1,000; Santa Cruz Biotechnology). The blots
were washed three times in TBS-Tween20 for 10 minutes
each, incubated with a horseradish peroxidase-conjugated
goat anti-rabbit IgG (1:5,000; Chemicon) or a horseradish
peroxidase-conjugated goat anti-mouse IgG (1:2,000;
Chemicon) for 1 hour at room temperature, and washed
four times in TBS-Tween20 for 10 minutes each. Protein
bands were visualized after incubation with SuperSignal
West Pico chemiluminescent substrate (Pierce Biotechnol-
ogy, Rockford, IL, USA) and exposure of high-performance
chemiluminescence film to the membrane surface in the
dark. Quantitative analysis of the intensity of the bands was
performed with Band Scan 5.0 software (Glyco, San
Leandro, CA, USA).
Primary microglia cultures
Primary microglial cells were cultured from newborn
C57/BL6 mice by a method described previously [16]. In
brief, the meninges were removed from the forebrains,
and tissues collected from forebrains were triturated into
single cells using fire-polished long Pasteur pipettes in
DMEM with high glucose. Cells were plated onto a
poly-L-lysine (Sigma)-coated (10 μg/ml) flask (75 cm2)
in media with 10% FBS and incubated at 37°C in 5%
CO2 in air and 95% humidity. The culture medium was
replenished after 24 hours and incubated for 8 days.
Microglial cells were then purified from the initial mixed
culture by sequential shaking at 180 ×g for 30 minutes
at room temperature. The resultant supernatant was col-
lected and centrifuged at 150× g for 5 minutes. The pellet
was suspended in complete medium and then plated in
24-well culture plates (Falcon, Franklin Lakes, NJ, USA).
After 1 hour, microglial cells were further purified by
washing twice with serum-free media and grown in new
complete media. To determine the purity of the micro-
glial cells, immunocytochemical analysis was carried out
using rat anti-mouse F4/80 antibody (1:50; Serotec).
These cultures were >95% F4/80 positive as determinedby immunocytochemistry, indicating that they were com-
posed of microglial cells.
Treatment
Microglia were treated with either hMSC co-culture in
which two cells interacted through contact, hMSC con-
ditioned media in which two-cell interaction is not avail-
able, or hMSC transwell culture in which two cells
interacted through diffusible molecules only.
Microglial cells were randomly divided into four groups.
Group 1, co-culture group: for co-culture plating, micro-
glia and hMSCs were mixed at a density of 1×105 cells/ml
for microglia and 5×104 cells/ml for hMSCs in DMEM
with high glucose and 10% FBS. Then 1 ml of the cell sus-
pension was plated in 24-well plates (Falcon) and allowed
to settle for 24 hours at 37°C in 5% CO2 in air.
Group 2, transwell culture group: 1×105 microglia per
well were plated in 1 ml DMEM with high glucose and
10% FBS in 24-well plates, and allowed to settle for
3 hours at 37°C in 5% CO2 in air and 95% humidity. In a
separate plate, 5×104 hMSCs per insert were plated in
300 μl DMEM with high glucose and 10% FBS in cell
culture inserts (1 μm pore size; Falcon), and allowed to
settle at 37°C in 5% CO2 in air. Cell culture inserts
containing the hMSCs were then inserted into the wells
containing the microglia and incubated for a further
21 hours before the start of the experiment.
Group 3, conditioned medium group: 2×105 hMSCs
were plated in 25 cm2 flask in 5 ml DMEM with high
glucose and 10% FBS. The culture medium was
replenished after 24 hours and incubated for 48 hours.
The resultant supernatant was collected and centrifuged
at 150× g for 5 minutes to remove cellular debris as
hMSC conditioned medium. Then 1×105 microglia per
well were plated in 1 ml medium in 24-well plates and
allowed to settle for 24 hours at 37°C in 5% CO2 in air
before addition of hMSC conditioned medium. Micro-
glial medium was removed and replaced with 1 ml
hMSC conditioned medium. Microglia were incubated
for a further 24 hours at 37°C in 5% CO2 in air.
Group 4, control group: 1×105 microglia were plated
in 24-well plates in 1 ml DMEM with high glucose and
10% FBS. Microglial cells were stimulated with 1 μg/ml
lipopolysaccharide (LPS; Sigma Chemical, St Louis, MO,
USA) for 12 hours based on the literature. The experi-
ments were carried out in triplicate and each experiment
was repeated three times.
Immunocytochemistry
The microglial cells were fixed with 4% paraformalde-
hyde in PBS (pH 7.4) for 20 minutes, blocked with nor-
mal serum for 1 hour, and then incubated with primary
antibody at 4°C overnight. Primary antibodies included:
rat anti-mouse F4/80 (1:50; Serotec), and mice anti-
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incubated at room temperature for 1 hour with goat anti-
rat FITC-conjugated IgG (1:50; Serotec) and goat anti-
mice Cy3-conjugated IgG (1:200; Chemicon). These cells
were counterstained with 4′,6-diamidino-2-phenylindole.Statistical analysis
Kaplan–Meier survival analysis and log-rank (Mantel–Cox)
analysis were used for survival comparisons. All other
statistical analyses were performed by one-way analysis
of variance followed by the Tukey post hoc test. All
group values are expressed as mean ± standard error of
the mean.Results
Human marrow stromal cell character
The cells isolated from bone marrow were hMSCs
showing the specific features defined by the Inter-
national Society for Cellular Therapy guidelines [17]. In
fact, they were adherent cells positive (≥95%) for CD73,
CD90 and CD105 and negative (≤2%) for the other
markers. Moreover, these cells were able to differentiate
to osteoblasts, chondroblasts and adipocytes after ex-
posure to specific conditioning media, as previously
shown [18].Figure 1 Human marrow stromal cell transplantation delayed disease
probability of disease onset (A) and survival (B) for Cu/Zn superoxide dism
intrathecal injection of human marrow stromal cells (hMSCs), relative to PB
improved by hMSC treatment (*P <0.01). (C) Effect of hMSC treatment on m
age. There was a significantly improved motor performance in G93A mice
Values are mean ± standard error of the mean.Human marrow stromal cell transplantation delayed
disease progression and prolonged survival in SOD1 mice
We investigated the therapeutic effect of intrathecally
transplanted hMSCs in G93A mice. As compared with
vehicle-treated SOD1 mice, hMSC-treated animals
showed a 6-day increase in median onset (104.8 ± 8.5
days vs. 98.7 ± 5.9 days, χ2 = 8.61, P <0.01; Figure 1A),
and mean survival of hMSC-treated animals was prolonged
by 14 days (154.82 ± 15.16 days vs. 140.47 ± 10.94 days,
χ2 = 10.13, P <0.01; Figure 1B).
Assessment of neuromuscular function was performed
by quantitative grip strength. SOD1 transgenic mice typic-
ally manifest a decline in motor performance after clinical
onset. Consistent with the finding of clinical observation,
hMSC-transplanted mice had significantly better motor
performance from 15 to 17 weeks of age than vehicle-
treated mice (P <0.01; Figure 1C).
Attenuation of neuronal loss by intrathecal administration
of human marrow stromal cells
We examined motor neurons in the lumbar spinal cord of
wild-type mice, hMSC-treated and vehicle-treated trans-
genic mice at the age of 11 and 15 weeks by Nissle stain-
ing (Figure 2A, B, C). Average motoneuron counts per
section in hMSC-treated mice were similar to counts in
vehicle-treated mice (23.6 ± 1.2 vs. 22.7 ± 1.7; P >0.05)
at the age of 11 weeks, whereas hMSC transplantationprogression and prolonged survival in SOD1 mice. Cumulative
utase 1 (SOD1) mice beginning at 8 weeks of age treated with
S treatment. Survival and onset of SOD1 mice were significantly
otor performance in G93A SOD1 transgenic mice from 8 weeks of
treated with hMSC injection from 15 to 17 weeks of age (*P <0.01).
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vehicle-treated mice at the age of 15 weeks (21.9 ± 1.6 vs.
17.4 ± 1.5; P <0.01; Figure 2D). The most vulnerable mo-
toneurons in ALS, which are the alpha neurons, were also
significantly preserved in hMSC-treated mice at the age of
15 weeks (4.7 ± 0.7 vs. 3.5 ± 0.4; P <0.05; Figure 2D).Inhibition of microglial activation and inflammatory
factors production by human marrow stromal cell
treatment
Activation of microglia was examined by CD11b immuno-
histochemistry in the spinal cord ventral grey of wild-type
mice and transgenic mice at the age of 11 and 15 weeks
(Figure 3A, B, C). Few microglia cells were observed in
wild-type mice at the age of 11 weeks (4.5 ± 0.6). How-
ever, we found a substantial increase in the number of
CD11b-positive microglia in transgenic mice at 11
weeks (51.3 ± 4.2) and 15 weeks (38.4 ± 3.6) of age in
SOD1 transgenic mice. Three different states of micro-
glial activation, ranging from resting to intermediate
and fully activated, were determined and then quanti-
fied. Notably, hMSC injection significantly reduced the
number of total microglial cells and activated microglia
in SOD1 transgenic mice at the ages of 11 weeks and
15 weeks (P <0.01; Figure 3D, E).Figure 2 Attenuation of neuronal loss by intrathecal administration o
spinal cord sections from 15-week-old wild-type mice (A) and Cu/Zn super
human marrow stromal cells (hMSCs) (C) at 200× magnification. (D) Quanti
Intrathecally injected hMSCs significantly preserved motor neuron loss in S
versus PBS alone).Activated microglia secrete various inflammatory mol-
ecules including TNFα and nitric oxide, so we examined
the protein levels of TNFα and iNOS of lumbar spinal
cord from wild-type mice and transgenic mice. Immuno-
blot analysis of iNOS in spinal cord extracts from
11-week-old hMSC-treated and vehicle-treated transgenic
mice revealed a single band of about 130 kDa, and in con-
trast no signal in wild-type mice (Figure 4A). The levels of
iNOS in SOD1 transgenic mice receiving hMSC trans-
plantation were lower by about 31% than those in vehicle-
treated mice (Figure 4B; P <0.01). Levels of TNFα
were significantly elevated in vehicle-treated SOD1 mice at
the age of 11 weeks compared with normal control mice
(Figure 4C; P <0.01). In accord with reduced microglial ac-
tivation, administration of hMSCs significantly reduced the
levels of TNFα by about 24% in transgenic mice at the age
of 11 weeks (Figure 4C; P <0.01).
Inhibition of microglial activation by human marrow
stromal cells in vitro
To investigate the mode of hMSCs inhibiting microglial
activation, microglia were treated with either hMSC co-
culture in which two cells interacted through contact,
hMSC transwell culture in which two cells interacted
through diffusible molecules only, or hMSC conditioned
medium in which two-cell interaction is not available.f human marrow stromal cells. Cresyl violet staining of the lumbar
oxide dismutase 1 (SOD1) transgenic mice treated with PBS (B) and
tative cell counts of motor neurons in the anterior horn sections.
OD1 transgenic mice at the age of 15 weeks (*P <0.01and **P <0.05
Figure 3 Inhibition of microglial activation by human marrow stromal cell treatment in SOD1 transgenic mice. Activation of microglia
were detected by CD11b immunoreactivity in the spinal cord ventral gray of wild-type mice (A), PBS-treated transgenic mice (B), and human
marrow stromal cell (hMSC)-treated transgenic mice (C) at the age of 15 weeks at 400× magnification. Higher-magnification images are shown in
the insert for resting microglia (A) and activated microglia (B). Quantitative cell counts of CD11b-positive microglia in the ventral gray of mice at
11 weeks of age (D) and 15 weeks of age (E). Intrathecally injected hMSCs significantly suppressed microglial activation in Cu/Zn superoxide
dismutase 1 (SOD1) transgenic mice (*P <0.01 versus PBS alone).
Zhou et al. Journal of Neuroinflammation 2013, 10:52 Page 7 of 11
http://www.jneuroinflammation.com/content/10/1/52Activated microglia stimulated with LPS showed an en-
larged shape and an intense immunoreactivity for F4/80
antigen (Figure 5B), whereas untreated microglia in cul-
tures showed a round shape (Figure 5A). Most of the
microglia in hMSCs-microglia co-cultures (Figure 5C)
and transwell cultures (Figure 5D) stimulated by LPS
were small and round, similar to resting state. This indi-
cated that the microglial cells were not fully activated by
LPS in the presence of hMSCs. However, hMSC condi-
tioned medium failed to suppress the microglia activa-
tion (Figure 5E).
Discussion
In this study, we suggest for the first time that intra-
thecally transplanted hMSCs can inhibit the inflamma-
tory response to exert a neuroprotective effect in SOD1
transgenic mice. This is evidenced by the decreases in
microglial activation, TNFα secretion and iNOS protein
expression. In addition, our study demonstrates that the
inhibitory effect on microglial activation of hMSCs is
through secretion of diffusible molecules adjusted to en-
vironmental cues.
Microglia play a critical role as resident immunocom-
petent and phagocytic cells within the central nervous
system. Activation is associated with increased nitric
oxide, reactive oxygen species and proinflammatory cy-
tokines, such as TNFα and IL-1β, which could generate
a neuroinflammatory environment. There is little doubtthat activated microglia can inflict significant damage on
neurons [19]. Targeting therapy to microglia may there-
fore be an effective strategy for ALS. Recently, the anti-
inflammatory effect of MSCs has generated a great deal
of interest. In vitro studies have shown that MSCs can
regulate immune cell proliferation, differentiation and
phenotype [8-10]. The anti-inflammatory properties of
MSCs have been well demonstrated in the treatment of
graft-versus-host disease after allogeneic hematopoietic
cell transplantation, and phase Ш clinical trials are cur-
rently ongoing [9]. In animal models of Parkinson dis-
ease [11], cerebral ischemia [12,13], Krabbe’s disease
[14] and ALS [15], studies suggested that administra-
tion of MSCs attenuated inflammation and improved
the motor function compared with control animals.
hMSC transplantation in transient global ischemic mice
downregulated >10% of the ischemic-induced genes,
most of which were involved in inflammatory and im-
mune responses [12]. These studies suggest that the
modulation of inflammatory and immune responses may
be one underlying mechanism of the neuroprotective ef-
fect of MSCs. Our study showed that hMSCs injected
intrathecally had an inhibitory effect on the microglial ac-
tivation and attendant inflammatory molecule production,
which is consistent with previous reports. Interestingly, we
observed the attenuation of neuronal loss by hMSC treat-
ment in the later period of SOD1 mice (15 weeks). In con-
trast, the inhibitory effect on microglial activation and
Figure 4 Inhibiting TNFα and iNOS production by human marrow stromal cell treatment in SOD1 transgenic mice. Lumbar spinal cord
tissues from wild-type mice, PBS-treated and human marrow stromal cell (hMSC)-treated transgenic mice at the age of 11 weeks are assayed for
inducible nitric oxide synthase (iNOS) protein expression by Immunoblot and TNFα level by ELISA. (A) Representative immunoblots for iNOS and
β-actin of the lumbar spinal cord from PBS-treated transgenic mice (1), wild-type mice (2) and hMSC-treated transgenic mice (3). (B) Quantitative
evaluation through optical densitometry of iNOS blot and relation to β-actin blot. The levels of iNOS in Cu/Zn superoxide dismutase 1 (SOD1)
transgenic mice receiving hMSC transplantation were significantly reduced compared with those in vehicle-treated mice (*P <0.01 versus PBS
alone). (C) Intrathecally injected hMSCs significantly decreased the spinal cord TNFα level in SOD1 transgenic mice (*P <0.01 versus PBS alone).
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period of SOD1 mice (11 weeks). Strong evidence accu-
mulated over recent years indicates that microglial cells
could be involved in the initiation and propagation of
motor neuronal cell damage in ALS [19]. Microglial acti-
vation played an important role in later disease progres-
sion, but not in disease onset and an early phase of disease
progression in SOD1 mice [6]. The neuroprotective effect
of hMSCs may thus be a consequence of the inhibition of
microglial activation that occurs in the early stages. Our
results therefore suggest that the neuroprotective effect of
hMSCs is consistent with the anti-inflammation mechan-
ism. It is well known that neurons can inhibit microglial
activation, but damaged neurons can activate resting
microglial cells [20]. hMSCs seem to have a similar effect
on microglial activation as normal neurons, which may
provide a novel concept for cytotherapy.
To further investigate the mode of hMSCs inhibiting
microglial activation, primary microglial cells were treated
with hMSC co-culture, hMSC transwell culture, or hMSC
conditioned medium in our studies. Our results suggested
that hMSCs reduced microglial activation through either
co-culture or transwell culture, which indicates that
hMSCs can inhibit microglial activation through diffusiblesoluble factors. The mode of hMSCs inhibiting microglial
activation through transwell culture provides important
evidence for our findings that intrathecal administration
of hMSCs may reduce microglial activation in SOD1 mice.
Intrathecal injection is a potential and practical route of
cell transplantation for central nervous system disease be-
cause of its minimal invasiveness and the fact that it would
bypass the blood–brain barrier. Whether intrathecally
injected cells can migrate into the parenchyma of the
spinal cord is still under debate [21-25]. The difference in
cell integration may be attributable to the animal models
and transplanted cells. The pial matter might act as a bar-
rier to invasion of cells into the spinal cord parenchyma,
so the injured pial layer in some animal models may allow
cells to more easily invade the spinal cord parenchyma.
Additionally, various cells have different migration behav-
ior. Habisch and colleagues showed that few intrathecally
injected hMSCs can integrate the spinal cord parenchyma
in SOD1 mice [25], which is consistent with our previous
study [5]. Encouragingly, studies found that intrathecally
transplanted cells were transported extensively by cerebro-
spinal fluid within the subarachnoid space, survived well
and even proliferated on the pial surface of the spinal cord
[21,23,24]. Thus it would not be unexpected that the
Figure 5 Effects of human marrow stromal cells on lipopolysaccharide-induced activation of microglia. Microglia were stimulated with
1 mg/μl lipopolysaccharide (LPS), and cultures were treated with human marrow stromal cells (hMSCs) in co-cultures and transwell cultures, and
hMSC conditioned medium (CM) (400× magnifications). Cells were fixed after 12 hours of stimulation with LPS. Microglial cells were
immunostained with an antibody against the F4/80 antigen, and hMSCs were stained with anti-HuNu antibody. In normal control cultures, the
majority of microglial cells were small and round. Upon stimulation with LPS, most of the microglial cells showed an enlarged shape. MSCs in
co-cultures and transwell cultures dramatically inhibited microglial activation, whereas hMSC CM has no significant effect on the
microglial activation.
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http://www.jneuroinflammation.com/content/10/1/52transplanted cells remaining in cerebrospinal fluid are
responsible for the neuroprotective effects through se-
creting some diffusible soluble factors to inhibit micro-
glial activation.
Mechanisms by which MSCs inhibit microglial activation
are still under investigation. The secretion of various cyto-
kines and neurotrophic factors is now believed to be the
main mechanism by which MSCs achieve their therapeutic
effects [10]. Studies have shown that hMSCs have the anti-
inflammation effects involving the secretion of prostaglan-
din E2, human leukocyte antigen G5, hepatocyte growth
factor, iNOS, indoleamine-2,3-dioxygenase, transforming
growth factor beta, leukemia-inhibitory factor, IL-10,
vascular endothelial growth factor and insulin-like
growth factor [10]. In addition, our study showed that
hMSC co-culture can also inhibit microglial activation.
Non-neural cells extend the survival of SOD1 mutantmotor neurons in SOD1 chimeric mice, which corre-
lates well with the proportion of wild-type cells within
the spinal cord [26]. The study suggests that it may be
feasible to achieve a more efficient therapeutic effect
by enhancing entry of transplanted cells into the spinal
cord parenchyma. The study of the method by which
the invasion of cells into the lesions can be promoted is
therefore necessary. Interestingly, conditioned medium
from hMSCs has no effect on microglial activation,
which suggests that hMSCs exert an anti-inflammation
effect through a positive process. Studies showed that
MSCs respond to certain cytokines such as IFNγ,
TNFα, IL-1α and IL-1β that could be present in the
local environment [10]. MSCs may therefore possibly
produce diffusible soluble factors adjusted to the needs
of tissue, which may be their most important biological
property.
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How cells injected intrathecally exert a neuroprotective ef-
fect is still unclear, because very few injected hMSCs were
detected in the parenchyma of the spinal cord. Under-
standing the mechanism of cell therapy will assist in the
improvement of therapeutic efficacy. Our current study
shows that intrathecally injected hMSCs can attenuate the
microglial activation through secretion of diffusible mole-
cules to exert a therapeutic effect in SOD1 transgenic
mice, which provides important evidence for cell trans-
plantation through cerebrospinal fluid. Further studies are
needed to explore the exact mechanism by which hMSCs
inhibit inflammation to facilitate the therapeutic effect.
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